Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology
The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on in...
| Autors principals: | , , , , , , |
|---|---|
| Format: | Article |
| Idioma: | English |
| Publicat: |
MDPI AG
2018-09-01
|
| Col·lecció: | Dentistry Journal |
| Matèries: | |
| Accés en línia: | http://www.mdpi.com/2304-6767/6/3/42 |